Aggregate Evidence Quality . | Grade C . |
---|---|
Benefits | Early detection and treatment of HTN in children with T1DM and T2DM may reduce future CV and kidney disease |
Risks, harm, cost | Risk of drug adverse effects and polypharmacy |
Benefit–harm assessment | Preponderance of benefit |
Intentional vagueness | None |
Role of patient preferences | Family concerns about additional testing and/or medication may need to be addressed |
Exclusions | None |
Strength | Weak to moderate recommendation |
Key references | 14,110,111,494 |
Aggregate Evidence Quality . | Grade C . |
---|---|
Benefits | Early detection and treatment of HTN in children with T1DM and T2DM may reduce future CV and kidney disease |
Risks, harm, cost | Risk of drug adverse effects and polypharmacy |
Benefit–harm assessment | Preponderance of benefit |
Intentional vagueness | None |
Role of patient preferences | Family concerns about additional testing and/or medication may need to be addressed |
Exclusions | None |
Strength | Weak to moderate recommendation |
Key references | 14,110,111,494 |